Filing Flows › Comparisons › NRXP vs KRSA
NRX Pharmaceuticals vs Korsana Biosciences: NRXP and KRSA compared
NRX Pharmaceuticals is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $1.0M for Korsana Biosciences (Q4 2025). Korsana Biosciences is more profitable, with an operating margin of -81.8% against -590.8%.
Where the money goes: NRXP and KRSA
NRX Pharmaceuticals (NRXP) · Q2 2026
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%, net loss $16.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Korsana Biosciences (KRSA) · Q4 2025
Korsana Biosciences, Q4 2025: revenue $1.0M (-43% year over year), operating margin -81.8%, net loss $799K, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| NRX Pharmaceuticals (NRXP) | Korsana Biosciences (KRSA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2025 |
| Revenue | $1.1M | $1.0M |
| Revenue growth, Y/Y | — | -43% |
| Operating margin | -590.8% | -81.8% |
| Net earnings | −$16.5M | −$799K |
| Net margin | — | -78.0% |
| Operating cash flow | −$8.9M | −$1.6M |
Where the revenue comes from
NRX Pharmaceuticals
- Therapy: $871K (79%)
- Procedures: $230K (21%)
Questions
Which is bigger, NRX Pharmaceuticals or Korsana Biosciences?
NRX Pharmaceuticals is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $1.0M for Korsana Biosciences (Q4 2025).
Is NRX Pharmaceuticals or Korsana Biosciences growing faster?
Korsana Biosciences is more profitable, with an operating margin of -81.8% against -590.8%.
More: NRX Pharmaceuticals earnings · how NRX Pharmaceuticals makes money · Korsana Biosciences earnings · how Korsana Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-K filed Mar 30, 2026). Fiscal quarters can end on different dates. Not investment advice.